Abstract
Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Letters in Drug Design & Discovery
Title: Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX
Volume: 6 Issue: 8
Author(s): Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny and Kamil Kuca
Affiliation:
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Abstract: Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Export Options
About this article
Cite this article as:
Karasova Zdarova Jana, Bajgar Jiri, Novotny Ladislav and Kuca Kamil, Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX, Letters in Drug Design & Discovery 2009; 6 (8) . https://dx.doi.org/10.2174/157018009789353419
DOI https://dx.doi.org/10.2174/157018009789353419 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation
Current Alzheimer Research Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Current Therapeutic Advances in Patients and Experimental Models of Huntington's Disease
Current Drug Targets Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research Special Invited Article Concussion, Sports and Psychiatry
Adolescent Psychiatry The Plasticity of the 7TMR Signaling Machinery and the Search for Pharmacological Selectivity
Current Pharmaceutical Design Assessing Schizophrenia-relevant Cognitive and Social Deficits in Mice: A Selection of Mouse Behavioral Tasks and Potential Therapeutic Compounds
Current Pharmaceutical Design The Neurophysiology of Hydrogen Sulfide
Inflammation & Allergy - Drug Targets (Discontinued) n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and Two Iodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere Human Brain Slices
Current Radiopharmaceuticals The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets The Role of the Endocannabinoid System in Eating Disorders: Neurochemical and Behavioural Preclinical Evidence
Current Pharmaceutical Design Comparative Anatomy, Physiology and In Vitro Models of the Blood-Brain and Blood-Retina Barrier
Current Medicinal Chemistry - Central Nervous System Agents Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Tachykinins and the Cardiovascular System
Current Drug Targets Nitric Oxide Control of Proliferation in Nerve Cells and in Tumor Cells of Nervous Origin
Current Pharmaceutical Design